AR125142A1 - Moléculas de unión terapéuticas - Google Patents
Moléculas de unión terapéuticasInfo
- Publication number
- AR125142A1 AR125142A1 ARP220100634A ARP220100634A AR125142A1 AR 125142 A1 AR125142 A1 AR 125142A1 AR P220100634 A ARP220100634 A AR P220100634A AR P220100634 A ARP220100634 A AR P220100634A AR 125142 A1 AR125142 A1 AR 125142A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- amino acid
- ccr9
- acid sequence
- region comprises
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 7
- 102100036303 C-C chemokine receptor type 9 Human genes 0.000 abstract 4
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 abstract 4
- 101000716070 Homo sapiens C-C chemokine receptor type 9 Proteins 0.000 abstract 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 2
- 102100021933 C-C motif chemokine 25 Human genes 0.000 abstract 1
- 102000004900 CC chemokine receptor 9 Human genes 0.000 abstract 1
- 108090001026 CC chemokine receptor 9 Proteins 0.000 abstract 1
- 101000897486 Homo sapiens C-C motif chemokine 25 Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7158—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Transplantation (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
La invención se refiere a moléculas de unión, tales como anticuerpos, que se unen al receptor de quimiocinas CCR9. Más particularmente, la invención se refiere al tratamiento de enfermedades o afecciones mediadas por CCR9, tales como la enfermedad Inflamatoria Intestinal (EII), y a métodos que, para la detección de CCR9, utilizan las moléculas de unión de la invención. Reivindicación 1: Una molécula de unión que se une a CCR9 y que comprende una región variable de cadena pesada (VH) que tiene un conjunto de CDR HCDR1, HCDR2 y HCDR3, y una región variable de cadena ligera (VL) que tiene un conjunto de CDR LCDR1, LCDR2 y LCDR3, en donde (a) la secuencia de aminoácidos de la región VH comprende HCDR1 de SEQ ID Nº 1, HCDR2 de SEQ ID Nº 2 y HCDR3 de SEQ ID Nº 3, y en donde la secuencia de aminoácidos de la región VL comprende LCDR1 de SEQ ID Nº 4, LCDR2 de SEQ ID Nº 5 y LCDR3 de SEQ ID Nº 6; (b) la secuencia de aminoácidos de la región VH comprende HCDR1 de SEQ ID Nº 7, HCDR2 de SEQ ID Nº 8 y HCDR3 de SEQ ID Nº 9, y en donde la secuencia de aminoácidos de la región VL comprende LCDR1 de SEQ ID Nº 10, LCDR2 de SEQ ID Nº 11 y LCDR3 de SEQ ID Nº 12; o (c) la secuencia de aminoácidos de la región VH comprende HCDR1 de SEQ ID Nº 13, HCDR2 de SEQ ID Nº 14 y HCDR3 de SEQ ID Nº 15, y en donde la secuencia de aminoácidos de la región VL comprende LCDR1 de SEQ ID Nº 16, LCDR2 de SEQ ID Nº 17 y LCDR3 de SEQ ID Nº 18 o en donde una cualquiera o más de dichas HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 y LCDR3 comprenden 1, 2 ó 3 sustituciones de aminoácidos en comparación con dichas secuencias. Reivindicación 19: Un agente terapéutico que comprende un anticuerpo anti-CCR9 como principio activo, en donde el anticuerpo anti-CCR9 compite con CCL25 por unirse a CCR9 humano.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163162603P | 2021-03-18 | 2021-03-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR125142A1 true AR125142A1 (es) | 2023-06-14 |
Family
ID=81327268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220100634A AR125142A1 (es) | 2021-03-18 | 2022-03-18 | Moléculas de unión terapéuticas |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20240174758A1 (es) |
| EP (1) | EP4308607A2 (es) |
| JP (1) | JP2024516769A (es) |
| KR (1) | KR20230158526A (es) |
| CN (1) | CN116997571A (es) |
| AR (1) | AR125142A1 (es) |
| AU (1) | AU2022236492A1 (es) |
| BR (1) | BR112023018331A2 (es) |
| CA (1) | CA3212630A1 (es) |
| CL (1) | CL2023002759A1 (es) |
| CO (1) | CO2023013566A2 (es) |
| CR (1) | CR20230488A (es) |
| EC (1) | ECSP23078844A (es) |
| IL (1) | IL305690A (es) |
| MX (1) | MX2023010917A (es) |
| TW (1) | TW202304985A (es) |
| WO (1) | WO2022195028A2 (es) |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| EP1186660A3 (fr) | 1985-03-30 | 2002-03-20 | KAUFFMAN, Stuart A. | Procédé d'obtension d'ADN, ARN, peptides, polypeptides ou protéines, par une technique de recombination d'ADN |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| DE3600905A1 (de) | 1986-01-15 | 1987-07-16 | Ant Nachrichtentech | Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5763192A (en) | 1986-11-20 | 1998-06-09 | Ixsys, Incorporated | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5750373A (en) | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0478627A4 (en) | 1989-05-16 | 1992-08-19 | William D. Huse | Co-expression of heteromeric receptors |
| CA2016842A1 (en) | 1989-05-16 | 1990-11-16 | Richard A. Lerner | Method for tapping the immunological repertoire |
| CA2016841C (en) | 1989-05-16 | 1999-09-21 | William D. Huse | A method for producing polymers having a preselected activity |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
| ATE275198T1 (de) | 1991-12-02 | 2004-09-15 | Medical Res Council | Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken. |
| US5766886A (en) | 1991-12-13 | 1998-06-16 | Xoma Corporation | Modified antibody variable domains |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| CA2229043C (en) | 1995-08-18 | 2016-06-07 | Morphosys Gesellschaft Fur Proteinoptimierung Mbh | Protein/(poly)peptide libraries |
| US6696248B1 (en) | 1995-08-18 | 2004-02-24 | Morphosys Ag | Protein/(poly)peptide libraries |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
| ES2571230T3 (es) | 1999-04-09 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedimiento para controlar la actividad de una molécula inmunofuncional |
| ES2353268T3 (es) | 1999-07-02 | 2011-02-28 | Morphosys Ag | Generacion de elementos de union especifica que se unen a (poli)peptidos codificados por fragmentos de adn genomico o est. |
| AU2002337935B2 (en) | 2001-10-25 | 2008-05-01 | Genentech, Inc. | Glycoprotein compositions |
| US7538195B2 (en) | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| EA010570B1 (ru) | 2002-11-07 | 2008-10-30 | Иммьюноджен, Инк. | Антитело к cd33 и способы его применения |
| GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| JP5470817B2 (ja) | 2008-03-10 | 2014-04-16 | 日産自動車株式会社 | 電池用電極およびこれを用いた電池、並びにその製造方法 |
| MY160680A (en) | 2009-09-22 | 2017-03-15 | Probiogen Ag | Process for producing molecules containing specialized glycan structures |
| JP6136279B2 (ja) | 2013-01-15 | 2017-05-31 | 株式会社ジェイテクト | 転がり軸受装置 |
| TWI503850B (zh) | 2013-03-22 | 2015-10-11 | Polytronics Technology Corp | 過電流保護元件 |
| TWI510996B (zh) | 2013-10-03 | 2015-12-01 | Acer Inc | 控制觸控面板的方法以及使用該方法的可攜式電腦 |
| EP2876114A1 (en) | 2013-11-25 | 2015-05-27 | Consejo Superior De Investigaciones Científicas | Antibodies against CCR9 and applications thereof |
| CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| US9816280B1 (en) | 2016-11-02 | 2017-11-14 | Matthew Reitnauer | Portable floor |
-
2022
- 2022-03-17 MX MX2023010917A patent/MX2023010917A/es unknown
- 2022-03-17 IL IL305690A patent/IL305690A/en unknown
- 2022-03-17 CR CR20230488A patent/CR20230488A/es unknown
- 2022-03-17 CA CA3212630A patent/CA3212630A1/en active Pending
- 2022-03-17 CN CN202280021611.7A patent/CN116997571A/zh active Pending
- 2022-03-17 US US18/550,757 patent/US20240174758A1/en active Pending
- 2022-03-17 US US17/697,041 patent/US20220306754A1/en active Pending
- 2022-03-17 AU AU2022236492A patent/AU2022236492A1/en active Pending
- 2022-03-17 BR BR112023018331A patent/BR112023018331A2/pt unknown
- 2022-03-17 KR KR1020237034201A patent/KR20230158526A/ko active Search and Examination
- 2022-03-17 EP EP22716861.4A patent/EP4308607A2/en active Pending
- 2022-03-17 WO PCT/EP2022/057029 patent/WO2022195028A2/en active Application Filing
- 2022-03-17 JP JP2023556501A patent/JP2024516769A/ja active Pending
- 2022-03-18 TW TW111110226A patent/TW202304985A/zh unknown
- 2022-03-18 AR ARP220100634A patent/AR125142A1/es unknown
-
2023
- 2023-09-15 CL CL2023002759A patent/CL2023002759A1/es unknown
- 2023-10-13 CO CONC2023/0013566A patent/CO2023013566A2/es unknown
- 2023-10-17 EC ECSENADI202378844A patent/ECSP23078844A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2023002759A1 (es) | 2024-02-16 |
| AU2022236492A9 (en) | 2023-11-09 |
| WO2022195028A2 (en) | 2022-09-22 |
| MX2023010917A (es) | 2023-09-27 |
| IL305690A (en) | 2023-11-01 |
| KR20230158526A (ko) | 2023-11-20 |
| CO2023013566A2 (es) | 2023-10-30 |
| TW202304985A (zh) | 2023-02-01 |
| CA3212630A1 (en) | 2022-09-22 |
| EP4308607A2 (en) | 2024-01-24 |
| CN116997571A (zh) | 2023-11-03 |
| CR20230488A (es) | 2023-12-12 |
| AU2022236492A1 (en) | 2023-10-26 |
| ECSP23078844A (es) | 2023-11-30 |
| BR112023018331A2 (pt) | 2023-12-12 |
| US20240174758A1 (en) | 2024-05-30 |
| WO2022195028A3 (en) | 2022-10-27 |
| US20220306754A1 (en) | 2022-09-29 |
| JP2024516769A (ja) | 2024-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR126019A1 (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
| PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
| PE20211767A1 (es) | Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y metodos de uso de anticuerpos anti-hla-g | |
| AR110719A1 (es) | Anticuerpos humanos a la toxina hemolisina a de s. aureus | |
| AR052959A1 (es) | Anticuerpos anti- ccr5 y usos de los mismos | |
| JP2017535257A5 (es) | ||
| RU2014109039A (ru) | Биспецифические антигенсвязывающие молекулы | |
| RU2014148502A (ru) | Человеческие антитела к fel d1 и способы их применения | |
| RU2010141584A (ru) | Антитело против csf-1r | |
| PE20221262A1 (es) | Anticuerpos terapeuticos y sus usos | |
| JP2013542194A5 (es) | ||
| NZ625403A (en) | Composition and method for diagnosis and treatment of diseases associated with neurite degeneration | |
| CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| RU2018102606A (ru) | Молекулы, связывающиеся с psl pseudomonas, и пути их применения | |
| PE20191079A1 (es) | Inmunoglobulinas y usos de estas | |
| JP2015503909A5 (es) | ||
| RU2017114968A (ru) | Связывающие молекулы, а именно антитела, способные связываться с l1cam (cd171) | |
| JP2015513903A5 (es) | ||
| JP2020514277A5 (es) | ||
| PE20220575A1 (es) | Anticuerpos multiespecificos de cadena pesada que se unen a cd22 y cd3 | |
| JP2024024114A5 (es) | ||
| AR098663A1 (es) | Anticuerpos multifuncionales que se unen a egfr y met | |
| AR110967A1 (es) | Anticuerpos miméticos fgf21 y su uso | |
| AR104906A1 (es) | Anticuerpos dirigidos a la proteína morfogenética ósea 9 (bmp9) y métodos a partir de estos |